La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Biodexa Pharmaceuticals a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Biodexa Pharmaceuticals..

Biodexa Pharmaceuticals (NASDAQ:BDRX) Azioni, Catena delle Opzioni

Biodexa Pharmaceuticals

Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.

Biodexa Pharmaceuticals plc - American Depositary Shares

Biodexa Pharmaceuticals PLC

BOMBARDIER 6.25% PFD A by Bombardier Inc.

Bombardier Inc

Press Releases

Biodexa Announces Recruitment of First Patient  in Phase 2 Study of Tolimidone in Type 1 Diabetes

Result of General Meeting

News

Biodexa Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In Phase 2a Study

Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP)

Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Results of Annual General Meeting

Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in  Familial Adenomatous Polyposis (FAP)

ADR Ratio Change

How Biodexa Is Racing To Get Its Phase 3 Program in FAP Under Way And Gain First-Mover Advantage in a $7Bn Addressable Market

ADR Ratio Change Effective

BDRX

Azitra

Bone Biologics

BioVie

Dermata Therapeutics, Inc. - Common Stock

Dermata Therapeutics

Ensysce Biosciences

Entero Therapeutics

Galecto

GRI Bio

GT Biopharma

Indaptus Therapeutics, Inc. - Common Stock

Indaptus Therapeutics

Pasithea Therapeutics Corp. - Common Stock

Pasithea Therapeutics

Mainz Biomed

Palisade Bio

PharmaCyte Biotech

Quoin Pharmaceuticals, Ltd. - American Depositary Shares

Quoin Pharmaceuticals

Revelation Biosciences, Inc. - Common Stock

Revelation Biosciences

Shuttle Pharmaceuticals Holdings, Inc. - common stock

Shuttle Pharmaceuticals

SILO Pharma

Silexion Therapeutics Corp - Ordinary Shares

Silexion Therapeutics

Alaunos Therapeutics, Inc. - Common Stock

Alaunos Therapeutics

Theriva Biologics

VivoSim Labs

Windtree Therapeutics, Inc. - Common Stock

Windtree Therapeutics

Longevity Health Holdings, Inc. - Common Stock

Longevity Health Holdings

Xenetic Biosciences

Ladenburg Thalmann

BDRX-logo

Biotech

PVLA

RXRX

Tempest Therapeutics, Inc. - Common Stock

TPST

How Biodexa Is Racing To Get Its Phase 3 Program In FAP Under Way And Gain First-Mover Advantage In A $7B Addressable Market

Screenshot 2025-06-17 at 8.31.13 PM

General

Screenshot 2025-03-18 at 8.36.36 PM

Fast Track Designation Secured, Successful Protocol Discussion With FDA And CROs Confirmed, Biodexa On Track To Initiate Funded Phase 3 FAP Trial Next Quarter

Untitled design - 2025-02-11T232646.924

Following Positive Phase 2 Results And Orphan Drug Designation, Biodexa&#39;s FAP Drug Receives FDA Fast Track Status

Image

Gaining Momentum, Biodexa Is Advancing Two Recent Acquisitions Through The Clinic

Untitled design - 2024-10-16T235234.675

Biodexa&#39;s MX-110 Continues To Show Promise In Recurrent Glioblastoma (rGBM), The Deadliest Brain Cancer

Screenshot 2024-07-10 at 9.15.35 PM

Biodexa Announces Additional Positive Results Of Phase 2 Trial Of eRapa In Treatment Of Precancerous Polyps In The GI Tract – Now 12-Month Data

Screenshot 2024-06-03 at 5.21.04 PM

Promising Phase 2 Results For Biodexa&#39;s eRapa™ Indicates Hope For FAP Patients Who Otherwise Have A 100% Lifetime Risk Of Colorectal Cancer

Screenshot 2024-05-08 at 7.48.00 PM

Biodexa Looks To Prevent Or Delay The Worst Outcomes For Adolescents And Young Adults With Devastating Precancerous Condition

Untitled design - 2024-03-28T172702.605

Biodexa&#39;s MTX110 Shows Promise In Extending Life Expectancy Against Aggressive Brain Cancers

Comments

Biodexa Pharmaceuticals

Biodexa Pharmaceuticals (BDRX) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO